xamoterol has been researched along with trimethoprim in 5 studies
| Studies (xamoterol) | Trials (xamoterol) | Recent Studies (post-2010) (xamoterol) | Studies (trimethoprim) | Trials (trimethoprim) | Recent Studies (post-2010) (trimethoprim) |
|---|---|---|---|---|---|
| 269 | 80 | 17 | 6,989 | 845 | 894 |
| Protein | Taxonomy | xamoterol (IC50) | trimethoprim (IC50) |
|---|---|---|---|
| Chain A, Dihydrofolate reductase | Bacillus anthracis | 77200 | |
| Chain A, dihydrofolate reductase (DHFR) | Bacillus anthracis | 77200 | |
| Dihydrofolate reductase | Mycobacterium avium | 0.2588 | |
| Dihydrofolate reductase | Homo sapiens (human) | 1.8206 | |
| Dihydrofolate reductase | Lacticaseibacillus casei | 0.3493 | |
| Dihydrofolate reductase type 1 | Escherichia coli | 0.25 | |
| Dihydrofolate reductase | Neisseria gonorrhoeae | 0.45 | |
| Thymidylate synthase | Homo sapiens (human) | 3.405 | |
| Dihydrofolate reductase | Staphylococcus aureus | 0.0875 | |
| Thymidylate synthase | Escherichia coli K-12 | 3.405 | |
| Dihydrofolate reductase | Escherichia coli K-12 | 0.6064 | |
| Bifunctional dihydrofolate reductase-thymidylate synthase | Plasmodium falciparum K1 | 0.01 | |
| Dihydrofolate reductase type 1 from Tn4003 | Staphylococcus aureus | 0.023 | |
| Dipeptidyl peptidase 4 | Rattus norvegicus (Norway rat) | 2.7 | |
| Dihydrofolate reductase | Pneumocystis carinii | 0.7061 | |
| Dihydrofolate reductase | Candida albicans | 0.1361 | |
| Dipeptidyl peptidase 4 | Homo sapiens (human) | 2.7 | |
| 5-hydroxytryptamine receptor 2B | Rattus norvegicus (Norway rat) | 0.45 | |
| Metabotropic glutamate receptor 5 | Rattus norvegicus (Norway rat) | 2.73 | |
| Mu-type opioid receptor | Cavia porcellus (domestic guinea pig) | 2.8 | |
| Bifunctional dihydrofolate reductase-thymidylate synthase | Toxoplasma gondii | 3.2206 | |
| Bifunctional dihydrofolate reductase-thymidylate synthase | Plasmodium berghei ANKA | 0.12 | |
| Dihydrofolate reductase | Streptococcus pneumoniae TIGR4 | 0.0297 | |
| Dihydrofolate reductase | Lactococcus lactis subsp. lactis Il1403 | 0.45 | |
| Dihydrofolate reductase | Bacillus anthracis | 4.77 | |
| Dihydrofolate reductase | Rattus norvegicus (Norway rat) | 1.244 | |
| Dihydrofolate reductase | Pneumocystis jirovecii | 0.092 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (60.00) | 29.6817 |
| 2010's | 2 (40.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Topliss, JG; Yoshida, F | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
5 other study(ies) available for xamoterol and trimethoprim
| Article | Year |
|---|---|
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |